- September 5, 2019– Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg…
- September 3, 2019SAN DIEGO, September 3, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment…
- August 12, 2019– Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic – SAN DIEGO, August…
- August 8, 2019SAN DIEGO, August 8, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment…
- August 1, 2019SAN DIEGO, August 1, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment…
- July 30, 2019SAN DIEGO, July 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment…
- July 16, 2019SAN DIEGO, July 16, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment…
- June 24, 2019SAN DIEGO, June 24, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment…
- June 21, 2019– Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated…
- June 4, 2019– Results confirm IMU-935 as a potent inverse agonist of RORγt with an IC50 of 24 nM, leading to potent inhibition…
